Pan-KRAS

Notes

original target text: Pan-KRAS inhibitor

KRAS is a small enzyme belonging to the RAS family of GTPases that functions as a molecular switch controlling cell growth and division. It cycles between an inactive, GDP-bound state and an active, GTP-bound state that transmits signals through the MAPK and PI3K pathways to drive proliferation. In many cancers—including pancreatic, colorectal, and lung tumors—mutations lock KRAS in its active configuration, producing continuous growth signaling independent of normal upstream control. For decades KRAS was considered difficult to drug because its surface lacks deep binding pockets and it binds GTP with very high affinity. Newer small molecules have found ways to engage the protein regardless of which specific mutation is present, rather than targeting only one variant. This 'pan-KRAS' approach is intended to cover the many different mutations found across patients and tumor types, and to remain effective even when a tumor develops a new mutation that escapes a narrower, mutation-specific drug. Because KRAS also performs normal functions in healthy tissue, modulating it broadly carries the possibility of affecting non-cancerous cells as well, a consideration relevant to how such agents are developed and used across the broader field of oncology.